Observational Study of Pharmacological Treatment for Premature Ejaculation Concurrent With Erectile Dysfunction

Erectile Dysfunction Clinical Trial

Official title:

Multicenter Study of the Efficacy and Safety of Dapoxetine Combined With Tadalafil in Men With Premature Ejaculation and Concomitant Erectile Dysfunction

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04361305
• Other study ID #: 0412
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: June 3, 2020
• Est. completion date: April 1, 2021

Study information

• Verified date: April 2020
• Source: Shanghai Jiao Tong University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Premature ejaculation (PE) is a common disease in the andrology clinic. Currently, the effectiveness and outcome differences of drug treatment still need to be studied and demonstrated. Premature ejaculation concurrent with erectile dysfunction (ED) is common in outpatient clinics. The preferred treatment plan for these patients still needs to be further studied and explored, and the difference in the efficacy of different treatment regiments remain to be evaluated.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 150
• Est. completion date: April 1, 2021
• Est. primary completion date: January 11, 2021
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. PE concurrent with ED: the IELT is less than 3 minutes, the PEDT score is =11 points, and 5=IIEF-5=21 points.

2. 18-60 years old, outpatient or physical examination population, with regular sex partners and regular sex life;

3. Having the data below,and willing to participate in the trial(1)Demographic information: age, gender, nationality, birthplace, etc;(2) Physical examination data: height, weight, abdominal circumference, blood pressure, heart rate, etc ;(3) Medical history data: history of present illness, past medical history, family history, etc;(4) Scale evaluation: Premature Ejaculation Diagnostic Tool (PEDT), Premature Ejaculation Profile (PEP), International Erectile Function Score-5(IIEF-5), Erectile Hardness Grading Score (EHGS), Clinical Global Impression of Change (GICC);

Exclusion Criteria:

1. Age <18 years or> 60 years;

2. There is a history of acute and chronic diseases, major trauma and surgery, etc;

3. A long history of medication;

4. There is a history of unstable myocardial infarction and cerebral infarction;

5. A history of cardiogenic shock, severe heart failure, severe ventricular arrhythmia, etc;

6. There are serious diseases such as malignant tumors, chronic liver and kidney diseases, etc.

Related Conditions & MeSH terms

• Erectile Dysfunction
• Premature Birth
• Premature Ejaculation

Intervention

Drug:
• Dapoxetine
30 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 8 weeks Tadalafil 5 mg tablets every day for 8 weeks
• Tadalafil
5 mg tablets every day for 8 weeks
• Tadalafil
5 mg tablets every day for 8 weeks

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Yan-Ping Huang

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The change of Premature Ejaculation Profile (PEP) at week 8	The PEP is a 4-question PRO that asks a respondent about his subjective sense of control over ejaculation, distress related to PE, interpersonal difficulty and satisfaction with sexual intercourse.	Baseline, Week 8
Primary	The change of International Index of Erectile Function -5(IIEF-5) at week 8		Baseline, Week 8
Secondary	Incidence of adverse reactions	To observe the safety of the two regiments in PE concurrent with ED patients	Baseline, Week 8
Secondary	The change of Erection Hardness Score (EHS)	Erection Hardness Score as a self-reporting measure that scored erection hardness on a 4 point scale. The aim was to help men, their partners and doctors diagnose erectile dysfunction.	Baseline, Week 8
Secondary	Clinical Global Impression of Change (GICC)	Clinical Global Impression is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.	Baseline, Week 8